Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anton Lindqvist

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Journal of Antimicrobial Chemotherapy|June 12, 2008
Nitrofurantoin resistance mechanism and fitness cost in Escherichia coliLinus Sandegren, Anton Lindqvist, Gunnar Kahlmeter, et al.
International Journal of Molecular Sciences|January 11, 2025
Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot TrialRosaura Casas, Andrea Tompa, Karin Åkesson, et al.
BMJ Open|October 31, 2022
Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocolJohnny Ludvigsson, Linnea Eriksson, Christoph Nowak, et al.
Nature Communications|May 24, 2017
Efficient protein production inspired by how spiders make silkNina Kronqvist, Médoune Sarr, Anton Lindqvist, et al.
Diabetologia|February 14, 2024
Assisting the implementation of screening for type 1 diabetes by using artificial intelligence on publicly available dataPedro F Teixeira, Tadej Battelino, Anneli Carlsson, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Journal of Antimicrobial Chemotherapy|June 12, 2008
Nitrofurantoin resistance mechanism and fitness cost in Escherichia coliLinus Sandegren, Anton Lindqvist, Gunnar Kahlmeter, et al.
International Journal of Molecular Sciences|January 11, 2025
Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot TrialRosaura Casas, Andrea Tompa, Karin Åkesson, et al.
BMJ Open|October 31, 2022
Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocolJohnny Ludvigsson, Linnea Eriksson, Christoph Nowak, et al.
Nature Communications|May 24, 2017
Efficient protein production inspired by how spiders make silkNina Kronqvist, Médoune Sarr, Anton Lindqvist, et al.
Diabetologia|February 14, 2024
Assisting the implementation of screening for type 1 diabetes by using artificial intelligence on publicly available dataPedro F Teixeira, Tadej Battelino, Anneli Carlsson, et al.
Pageof 1